Medicare covers many of the cognitive and diagnostic tests used to evaluate Alzheimer’s disease, but coverage varies depending on the type of test, your specific Medicare plan, and whether your doctor orders the test as part of a medically necessary evaluation. Original Medicare (Part A and Part B) covers cognitive screening tests like the Montreal Cognitive Assessment (MoCA) and Mini-Cog when ordered by your doctor during an office visit, and it covers imaging tests such as MRI and CT scans when they’re deemed medically necessary to rule out other causes of cognitive decline. However, Medicare does not cover all testing, and some newer biomarker tests have only recently begun receiving coverage. For example, if you visit your primary care doctor with concerns about memory loss, Medicare Part B will cover the cost of a cognitive screening test (typically $0-$50 depending on your deductible and copay), but if that screening suggests Alzheimer’s, the subsequent MRI or PET scan to confirm the diagnosis may require prior authorization, and some tests—such as blood-based amyloid and tau biomarker tests—have only recently been added to Medicare’s covered services list.
Table of Contents
- What Types of Alzheimer’s Tests Does Medicare Actually Cover?
- Medicare Part B Coverage Details and Important Limitations
- Brain Imaging Tests and Their Medicare Coverage Status
- Getting Prior Authorization and Approval for Alzheimer’s Testing
- Coverage Gaps and What You May Pay Out of Pocket for Alzheimer’s Testing
- Blood-Based Biomarker Testing and Recent Medicare Changes
- Neurologist and Memory Clinic Testing Under Medicare Coverage
What Types of Alzheimer’s Tests Does Medicare Actually Cover?
Medicare’s coverage for Alzheimer’s testing includes several categories: cognitive and neuropsychological screening tests performed in a doctor’s office, imaging studies to rule out other causes of dementia, laboratory work to assess overall health and rule out metabolic causes of cognitive decline, and increasingly, blood-based biomarker tests. The most commonly covered screening tests are brief cognitive assessments like the Montreal Cognitive Assessment (MoCA), the Mini-Cog, and the Mini-Mental State Examination (MMSE), which take 10 to 30 minutes to complete in an outpatient setting and are covered when billed as part of an office visit with medical necessity documentation.
Imaging tests covered by Medicare include brain MRI scans (which can identify structural changes, stroke, or tumor), CT scans (a faster alternative to MRI), and PET scans using the tracer 18F-florbetapir (Amyvid), which can visualize amyloid deposits in the brain—a hallmark of Alzheimer’s pathology. A patient presenting with memory complaints might undergo an MRI ordered by their neurologist; Medicare would typically cover the scan at 80 percent of the approved amount after the Part B deductible, with the patient responsible for the remaining 20 percent coinsurance plus any out-of-network facility charges.
Medicare Part B Coverage Details and Important Limitations
Medicare Part B covers cognitive testing when ordered by your physician as part of a medically necessary evaluation for cognitive impairment or dementia, and most primary care offices have these screening tools available at no additional cost beyond the standard office visit copay or coinsurance. The coverage also extends to more comprehensive neuropsychological testing performed by psychologists or neuropsychologists when the doctor documents that such testing is necessary to establish a diagnosis or assess cognitive function before starting Alzheimer’s medications.
However, Medicare does not cover cognitive or neuropsychological testing for general wellness purposes, for concerns that fall outside the scope of dementia evaluation, or when ordered by non-physician providers in some cases depending on state licensing and the specific clinical setting. Additionally, comprehensive neuropsychological batteries—which can cost $1,500 to $3,000 out-of-pocket at specialty centers—are covered only if Medicare’s local coverage determination (LCD) in your region includes them, and even then, coverage is limited to one comprehensive battery per three years in many parts of the country. A warning: some insurers and Medicare Advantage plans impose additional restrictions beyond the standard Medicare coverage rules, so you must verify your specific plan’s requirements before undergoing testing.
Brain Imaging Tests and Their Medicare Coverage Status
medicare Part B covers brain MRI scans, CT scans, and certain PET scans when they are ordered by your doctor and deemed medically necessary for the evaluation of cognitive decline or dementia. The amyloid PET scan using florbetapir (Amyvid) is now covered by Medicare when ordered by a neurologist or another qualified physician for patients with cognitive impairment who are being evaluated for possible Alzheimer’s disease, representing a significant change from previous years when this test was not covered.
The cost to you depends on whether your provider is in-network and your specific deductible and coinsurance amounts; for a typical MRI scan, you would pay your annual Part B deductible ($226 in 2024) plus 20 percent coinsurance of the approved amount. A limitation to understand: Medicare covers diagnostic imaging to evaluate cognitive decline, but it does not cover follow-up imaging solely for monitoring disease progression in asymptomatic patients or for research purposes—each scan must be medically justified in the clinical context. Additionally, some regional Medicare Administrative Contractors have stricter local coverage determinations, meaning that a PET scan approved in one state might not be covered in another, and you should confirm coverage before scheduling any imaging study.
Getting Prior Authorization and Approval for Alzheimer’s Testing
Before undergoing advanced testing such as amyloid or tau PET scans, a neurologist’s office typically submits a prior authorization request to Medicare, which requires documentation that the patient has cognitive impairment and that imaging is medically necessary to evaluate or diagnose possible Alzheimer’s disease. This process usually takes 3 to 10 business days, though emergency authorizations can sometimes be obtained faster if the clinical situation warrants it.
To facilitate approval, your physician should document the reason for testing in their medical record (such as “patient reports progressive memory loss over 12 months” or “Mini-Cog score 2/3 suggesting impairment”), include any relevant cognitive screening results, and demonstrate that the test will directly influence clinical decision-making. A practical strategy is to start with less expensive screening tests (cognitive assessments and standard MRI) before pursuing specialized PET imaging, as this sequence is more likely to satisfy Medicare’s medical necessity requirements. Know that if your Medicare Advantage plan is involved, the authorization and coverage rules may differ from Original Medicare, so contact your plan’s member services line before scheduling testing.
Coverage Gaps and What You May Pay Out of Pocket for Alzheimer’s Testing
Medicare does not cover blood-based biomarker tests (such as plasma phosphorylated tau or amyloid-beta levels) through most Medicare Advantage plans, though some coverage has recently begun through Original Medicare for specific tests in specific clinical contexts—this is an area of rapid change. Genetic testing for APOE status (the apolipoprotein E gene, which influences Alzheimer’s risk) is generally not covered by Medicare, even though some research and clinical contexts find it informative.
A significant warning: if you receive testing at an out-of-network imaging facility or through a Medicare Advantage plan that imposes stricter limits than Original Medicare, you could face substantial out-of-pocket costs ranging from a few hundred dollars for a standard MRI to $2,000 to $5,000 for specialized PET imaging. Additionally, if your doctor orders testing without proper prior authorization or if the test falls outside your plan’s coverage guidelines, Medicare may deny the claim, and you could be responsible for the entire facility and professional fee—potentially $1,500 to $3,000 for a single imaging study. Always request an Explanation of Benefits (EOB) after testing to confirm that Medicare processed the claim as expected.
Blood-Based Biomarker Testing and Recent Medicare Changes
Recent approvals have expanded Medicare coverage to include blood-based biomarker tests such as phosphorylated tau (p-tau181 and p-tau217) and plasma phosphorylated tau/amyloid-beta ratios, which can detect Alzheimer’s pathology without requiring expensive PET imaging or lumbar puncture. These tests, available through laboratories such as Quest Diagnostics and LabCorp, are far less invasive and significantly cheaper than imaging—typically $200 to $500 per test—and can help physicians determine whether cognitive decline is due to Alzheimer’s or other causes.
Coverage for these blood tests is still evolving, and not all blood-based biomarker tests are covered by all Medicare plans or in all regions, so your physician should verify coverage before ordering. The advantage is that a positive blood biomarker test may reduce the need for expensive PET imaging in some patients, thereby decreasing overall out-of-pocket spending.
Neurologist and Memory Clinic Testing Under Medicare Coverage
When you see a neurologist or visit a specialized memory clinic for Alzheimer’s evaluation, Medicare covers the specialist visit itself (typically billed as an office visit with standard copay or coinsurance), and any testing ordered by the specialist follows the same coverage rules as testing from your primary care doctor. A patient referred to a memory clinic might undergo an extensive neuropsychological battery costing $2,000 to evaluate memory, language, attention, and executive function; Medicare would cover this comprehensive testing if the clinic is in-network and the test is deemed medically necessary, though the patient would typically pay 20 percent coinsurance on the approved amount. Memory clinics and specialized neurologists may also perform additional assessments such as gait evaluation, functional capacity evaluation, and caregiver interviews, many of which are covered as part of the clinical encounter when documented properly in the medical record.
- —
